ArticleBMC biology2026
The immune protection of OMP16-specific IgM against Brucella infection.
Article in BMC biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBrucellosis, a severe zoonotic infectious disease, poses substantial economic and health threats globally. The intracellular survival strategy of Brucella complicates disease control, highlighting the need for novel immunotherapeutic strategies such as antibody-based therapies and multi-epitope vaccines.
resultsThis study generated two IgM monoclonal antibodies (D3 and F5) against the conserved outer membrane protein OMP16 of Brucella using hybridoma technology. Peptide scanning and Western blot identified their linear epitopes (D3:
conclusionsOur study underscores the role of IgM antibodies in combating Brucella infection, offers insights for antibody-based immunotherapy, and provides a theoretical foundation for developing multi-epitope vaccines based on the conserved epitopes and critical residues.
Indexed as
Identifiers
42458412What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.